174 related articles for article (PubMed ID: 30794795)
41. Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier.
Shan Y; Cen Y; Zhang Y; Tan R; Zhao J; Nie Z; Zhang J; Yu S
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):279-289. PubMed ID: 35112329
[TBL] [Abstract][Full Text] [Related]
42. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
43. Improved In Vitro-In Vivo Correlation by Using the Unbound-Fraction-Adjusted IC
Imai S; Arai T; Yamada T; Niwa M
Pharm Res; 2020 Oct; 37(12):230. PubMed ID: 33123823
[TBL] [Abstract][Full Text] [Related]
44. Ensemble Machine Learning Approaches Based on Molecular Descriptors and Graph Convolutional Networks for Predicting the Efflux Activities of MDR1 and BCRP Transporters.
Adachi A; Yamashita T; Kanaya S; Kosugi Y
AAPS J; 2023 Sep; 25(5):88. PubMed ID: 37700207
[TBL] [Abstract][Full Text] [Related]
45. Abundance of
Brukner AM; Billington S; Benifla M; Nguyen TB; Han H; Bennett O; Gilboa T; Blatch D; Fellig Y; Volkov O; Unadkat JD; Ekstein D; Eyal S
Mol Pharm; 2021 Jun; 18(6):2263-2273. PubMed ID: 34008992
[TBL] [Abstract][Full Text] [Related]
46. Efflux transport of estrogen glucuronides by human MRP2, MRP3, MRP4 and BCRP.
Järvinen E; Deng F; Kidron H; Finel M
J Steroid Biochem Mol Biol; 2018 Apr; 178():99-107. PubMed ID: 29175180
[TBL] [Abstract][Full Text] [Related]
47. P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability.
Martínez-Chávez A; van Hoppe S; Rosing H; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
Mol Pharm; 2019 Sep; 16(9):3842-3852. PubMed ID: 31329454
[TBL] [Abstract][Full Text] [Related]
48. Efflux transporter breast cancer resistance protein dominantly expresses on the membrane of red blood cells, hinders partitioning of its substrates into the cells, and alters drug-drug interaction profiles.
Shi P; Liao M; Chuang BC; Griffin R; Shi J; Hyer M; Fallon JK; Smith PC; Li C; Xia CQ
Xenobiotica; 2018 Nov; 48(11):1173-1183. PubMed ID: 29098941
[TBL] [Abstract][Full Text] [Related]
49. Placental BCRP/ABCG2 Transporter Prevents Fetal Exposure to the Estrogenic Mycotoxin Zearalenone.
Szilagyi JT; Gorczyca L; Brinker A; Buckley B; Laskin JD; Aleksunes LM
Toxicol Sci; 2019 Apr; 168(2):394-404. PubMed ID: 30576553
[TBL] [Abstract][Full Text] [Related]
50. Roles of P-glycoprotein and multidrug resistance protein in transporting para-aminosalicylic acid and its N-acetylated metabolite in mice brain.
Hong L; Xu C; O'Neal S; Bi HC; Huang M; Zheng W; Zeng S
Acta Pharmacol Sin; 2014 Dec; 35(12):1577-85. PubMed ID: 25418377
[TBL] [Abstract][Full Text] [Related]
51. Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective.
Goncalves J; Bicker J; Alves G; Fortuna A; Falcao A
Curr Drug Metab; 2018; 19(12):1021-1041. PubMed ID: 29956624
[TBL] [Abstract][Full Text] [Related]
52. Brain region-specific regulation of histone acetylation and efflux transporters in mice.
You D; Shin HM; Mosaad F; Richardson JR; Aleksunes LM
J Biochem Mol Toxicol; 2019 Jun; 33(6):e22318. PubMed ID: 30897286
[TBL] [Abstract][Full Text] [Related]
53. Magnolol and Honokiol Inhibited the Function and Expression of BCRP with Mechanism Exploration.
Yu CP; Li PY; Chen SY; Lin SP; Hou YC
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885972
[TBL] [Abstract][Full Text] [Related]
54. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid.
Ren G; Qin Z; Yang N; Chen H; Fu K; Lu C; Lu Y; Li N; Zhang Y; Chen X; Zhao D
Chem Biol Interact; 2020 Jun; 324():109097. PubMed ID: 32305507
[TBL] [Abstract][Full Text] [Related]
55. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides.
Bircsak KM; Richardson JR; Aleksunes LM
J Biochem Mol Toxicol; 2013 Feb; 27(2):157-64. PubMed ID: 23169446
[TBL] [Abstract][Full Text] [Related]
57. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
[TBL] [Abstract][Full Text] [Related]
58. P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice.
F Martins ML; Loos NHC; El Yattouti M; Offeringa L; Heydari P; Hillebrand MJX; Lebre MC; Beijnen JH; Schinkel AH
Pharm Res; 2023 Aug; 40(8):1885-1899. PubMed ID: 37344602
[TBL] [Abstract][Full Text] [Related]
59. Aluminum and ABC transporter activity.
Oezen G; Kraus L; Schentarra EM; Bolten JS; Huwyler J; Fricker G
Environ Toxicol Pharmacol; 2024 Jun; 108():104451. PubMed ID: 38648870
[TBL] [Abstract][Full Text] [Related]
60. Bile duct ligation enhances AZT CNS toxicity partly by impairing the expression and function of BCRP in rat brain.
Qin YY; Xu P; Wu T; Qian CQ; Fan YL; Gen DH; Zhu L; Kong WM; Yang HY; Xu F; Yang YT; Liu L; Liu XD
Acta Pharmacol Sin; 2020 Feb; 41(2):181-191. PubMed ID: 31142800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
